{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T22:53:40Z","timestamp":1788648820301,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016244","name":"Health Foundation Limburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016244","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejso.2024.108465","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T10:06:23Z","timestamp":1717581983000},"page":"108465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Surgical outcomes and prognosis of HER2+ invasive breast cancer patients with a DCIS component treated with breast-conserving surgery after neoadjuvant systemic therapy"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1024-3519","authenticated-orcid":false,"given":"Roxanne A.W.","family":"Ploumen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva L.","family":"Claassens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8226-8665","authenticated-orcid":false,"given":"Loes F.S.","family":"Kooreman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristien B.M.I.","family":"Keymeulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje A.C.E.","family":"van Kats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander M.J.","family":"van Kuijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0273-824X","authenticated-orcid":false,"given":"Sabine","family":"Siesling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiemo J.A.","family":"van Nijnatten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein L.","family":"Smidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2024.108465_bib1","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s12282-020-01076-1","article-title":"Health-related quality of life following breast reconstruction compared to total mastectomy and breast-conserving surgery among breast cancer survivors: a systematic review and meta-analysis","volume":"27","author":"Zehra","year":"2020","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ejso.2024.108465_bib2","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1200\/JCO.2013.53.3935","article-title":"Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer","volume":"32","author":"Moran","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2024.108465_bib3","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1016\/j.ejca.2010.07.043","article-title":"Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy","volume":"46","author":"Houssami","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2024.108465_bib4","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s10549-021-06500-4","article-title":"Surgical margin status and survival outcomes of breast cancer patients treated with breast-conserving surgery and whole-breast irradiation after neoadjuvant chemotherapy","volume":"194","author":"Cheun","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejso.2024.108465_bib5","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1245\/s10434-018-6702-4","article-title":"Margins in breast-conserving surgery after neoadjuvant therapy","volume":"25","author":"Choi","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2024.108465_bib6","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1245\/s10434-019-08089-x","article-title":"Impact of surgical margins in breast cancer after preoperative systemic chemotherapy on local recurrence and survival","volume":"27","author":"Wimmer","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2024.108465_bib7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/jncimonographs\/lgv023","article-title":"International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the fifth symposium on primary systemic therapy in the management of operable breast cancer, cremona, Italy (2013)","volume":"2015","author":"Amoroso","year":"2015","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.ejso.2024.108465_bib8","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1245\/s10434-011-2108-2","article-title":"Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer","volume":"19","author":"Kaufmann","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2024.108465_bib9","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1200\/JCO.1998.16.8.2672","article-title":"Effect of preoperative chemotherapy on the outcome of women with operable breast cancer","volume":"16","author":"Fisher","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2024.108465_bib10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10549-016-3862-4","article-title":"Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study","volume":"158","author":"Doebar","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejso.2024.108465_bib11","doi-asserted-by":"crossref","first-page":"9934","DOI":"10.1038\/s41598-019-46309-2","article-title":"Overall survival is improved when DCIS accompanies invasive breast cancer","volume":"9","author":"Kole","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejso.2024.108465_bib12","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1245\/s10434-008-0054-4","article-title":"Predictors of surgical margin status in breast-conserving surgery within a breast screening program","volume":"15","author":"Kurniawan","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2024.108465_bib13","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1245\/s10434-016-5532-5","article-title":"Predictors of surgical margin following breast-conserving surgery: a large population-based cohort study","volume":"23","author":"van Deurzen","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2024.108465_bib14","first-page":"1027","article-title":"The intraductal component of breast cancer is poorly responsive to neo-adjuvant chemotherapy","volume":"9","author":"Wu","year":"2002","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ejso.2024.108465_bib15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10549-021-06235-2","article-title":"Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer","volume":"189","author":"Groen","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejso.2024.108465_bib16","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s10549-011-1621-0","article-title":"Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy\/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40)","volume":"132","author":"von Minckwitz","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejso.2024.108465_bib17","series-title":"Dutch guideline \u2018treatment of breast cancer\u2019 (Richtlijn \u2018Behandeling van het Mammacarcinoom\u2019)","year":"2008"},{"key":"10.1016\/j.ejso.2024.108465_bib18","series-title":"Dutch guideline \u2018treatment of breast cancer\u2019 (Richtlijn \u2018Behandeling van het Mammacarcinoom\u2019)","year":"2012"},{"key":"10.1016\/j.ejso.2024.108465_bib19","series-title":"Dutch guideline \u2018treatment of breast cancer\u2019 (Richtlijn \u2018Behandeling van het Mammacarcinoom\u2019)","year":"2017"},{"key":"10.1016\/j.ejso.2024.108465_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju288","article-title":"Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research","volume":"106","author":"Moossdorff","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejso.2024.108465_bib21","series-title":"Flexible imputation of missing data","first-page":"29","article-title":"Multiple imputation","author":"Rubin","year":"2018"},{"key":"10.1016\/j.ejso.2024.108465_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-017-4598-5","article-title":"Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes","volume":"168","author":"Volders","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejso.2024.108465_bib23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejso.2018.09.027","article-title":"Breast conserving therapy after neoadjuvant chemotherapy; data from the Dutch Breast Cancer Audit","volume":"45","author":"Spronk","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2024.108465_bib24","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1245\/s10434-021-10533-w","article-title":"Margin width and local recurrence in patients undergoing breast conservation after neoadjuvant chemotherapy","volume":"29","author":"Mrdutt","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2024.108465_bib25","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.7150\/jca.20871","article-title":"DCIS margins and breast conservation: MD Anderson cancer center multidisciplinary practice guidelines and outcomes","volume":"8","author":"Kuerer","year":"2017","journal-title":"J Cancer"},{"key":"10.1016\/j.ejso.2024.108465_bib26","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1245\/s10434-015-4876-6","article-title":"Microcalcifications in 1657 patients with pure ductal carcinoma in situ of the breast: correlation with clinical, histopathologic, biologic features, and local recurrence","volume":"23","author":"Rauch","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2024.108465_bib27","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1002\/(SICI)1097-0142(19961101)78:9<1921::AID-CNCR12>3.0.CO;2-#","article-title":"Pathologic margin involvement and the risk of recurrence in patients treated with breast-conserving therapy","volume":"78","author":"Gage","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2024.108465_bib28","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2024.108465_bib29","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1200\/JCO.22.02241","article-title":"Pathologic complete response and individual patient prognosis after neoadjuvant chemotherapy plus anti-human epidermal growth factor receptor 2 therapy of human epidermal growth factor receptor 2-positive early breast cancer","volume":"41","author":"van Mackelenbergh","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2024.108465_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrac028","article-title":"Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis","volume":"6","author":"Davey","year":"2022","journal-title":"BJS Open"},{"key":"10.1016\/j.ejso.2024.108465_bib31","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1245\/s10434-019-07533-2","article-title":"Patient selection for clinical trials eliminating surgery for HER2-positive breast cancer treated with neoadjuvant systemic therapy","volume":"26","author":"Sun","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2024.108465_bib32","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2020.3025","article-title":"Changes in reoperation after publication of consensus guidelines on margins for breast-conserving surgery: a systematic review and meta-analysis","volume":"155","author":"Marinovich","year":"2020","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ejso.2024.108465_bib33","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jamcollsurg.2018.01.050","article-title":"Evaluating the effect of margin consensus guideline publication on operative patterns and financial impact of breast cancer operation","volume":"227","author":"Bhutiani","year":"2018","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.ejso.2024.108465_bib34","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1007\/s00330-023-09547-7","article-title":"Imaging findings for response evaluation of ductal carcinoma in situ in breast cancer patients treated with neoadjuvant systemic therapy: a systematic review and meta-analysis","volume":"33","author":"Ploumen","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ejso.2024.108465_bib35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10549-023-07012-z","article-title":"Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis","volume":"201","author":"Ploumen","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejso.2024.108465_bib36","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.21037\/gs-23-137","article-title":"Extensive intraductal component as a factor determining local recurrence of breast cancer: a systematic review and meta-analysis","volume":"12","author":"Polchai","year":"2023","journal-title":"Gland Surg"},{"key":"10.1016\/j.ejso.2024.108465_bib37","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/jso.26749","article-title":"Tumor margins that lead to reoperation in breast cancer: a retrospective register study of 4,489 patients","volume":"125","author":"Lepom\u00e4ki","year":"2022","journal-title":"J Surg Oncol"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798324005171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798324005171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T19:19:44Z","timestamp":1737314384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798324005171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0748798324005171"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2024.108465","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surgical outcomes and prognosis of HER2+ invasive breast cancer patients with a DCIS component treated with breast-conserving surgery after neoadjuvant systemic therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2024.108465","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108465"}}